Latest news for health care topics. Include medical news , health insurance , therapy and vaccine news

Wednesday, March 1, 2017

Kite Pharma Inc (KITE) Receives Average Rating of “Buy” from Analysts stat : The Cerbat Gem

Stifel Nicolaus reaffirmed a "buy" rating on shares of Kite Pharma in a research note on Monday, December 12th. FBR & Co reaffirmed a "buy" rating on shares of Kite Pharma in a research note on Tuesday, December 6th. Equities analysts predict that Kite Pharma will post ($5.48) earnings per share for the current fiscal year. BTIG Research reaffirmed a "hold" rating on shares of Kite Pharma in a research note on Tuesday, November 22nd. Vetr cut Kite Pharma from a "strong-buy" rating to a "sell" rating and set a $63.65 target price on the stock.



Kite Pharma Inc (KITE) Receives Average Rating of
"Kite Pharma Inc (KITE) Issues Earnings Results" was originally reported by Sports Perspectives and is owned by of Sports Perspectives. Receive News & Ratings for Kite Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter. Kite Pharma Company ProfileKite Pharma, Inc is a clinical-stage biopharmaceutical company. Kite Pharma Inc (NASDAQ:KITE) released its quarterly earnings results on Monday. Kite Pharma had a negative return on equity of 39.26% and a negative net margin of 994.89%.

Kite Pharma Inc (KITE) Issues Earnings Results
"Kite Pharma Inc (KITE) Announces Quarterly Earnings Results, Beats Estimates By $0.44 EPS" was first published by Sports Perspectives and is owned by of Sports Perspectives. The firm's 50-day moving average price is $51.93 and its 200 day moving average price is $52.03. Kite Pharma Company ProfileKite Pharma, Inc is a clinical-stage biopharmaceutical company. Receive News & Ratings for Kite Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter. Kite Pharma had a negative return on equity of 39.26% and a negative net margin of 994.89%.



collected by :Lucy William

To follow all the new news about Health care

No comments:

Post a Comment